about
Amyloid-beta Alzheimer targets - protein processing, lipid rafts, and amyloid-beta poresIntegrating network, sequence and functional features using machine learning approaches towards identification of novel Alzheimer genesWet or dry: translatable "water mazes" for mice and humansOverexpression of Swedish mutant APP in aged astrocytes attenuates excitatory synaptic transmissionA genetically immortalized human stem cell line: a promising new tool for Alzheimer's disease therapy.Do CSF Biomarkers Predict Progression to Cognitive Impairment in Parkinson's disease patients? A Systematic Review.Protein Tyrosine Phosphatase 1B (PTP1B): A Potential Target for Alzheimer's Therapy?Therapeutic Actions of the Thiazolidinediones in Alzheimer's Disease.Combining Cerebrospinal Fluid Biomarkers and Neuropsychological Assessment: A Simple and Cost-Effective Algorithm to Predict the Progression from Mild Cognitive Impairment to Alzheimer's Disease Dementia.A Novel, Multi-Target Natural Drug Candidate, Matrine, Improves Cognitive Deficits in Alzheimer's Disease Transgenic Mice by Inhibiting Aβ Aggregation and Blocking the RAGE/Aβ Axis.Thiamine Deficiency and Neurodegeneration: the Interplay Among Oxidative Stress, Endoplasmic Reticulum Stress, and Autophagy.ErbB2 regulates autophagic flux to modulate the proteostasis of APP-CTFs in Alzheimer's disease.Re-evaluation of soluble APP-α and APP-β in cerebrospinal fluid as potential biomarkers for early diagnosis of dementia disorders.Clinical Bioavailability of the Novel BACE1 Inhibitor Lanabecestat (AZD3293): Assessment of Tablet Formulations Versus an Oral Solution and the Impact of Gastric pH on Pharmacokinetics.Schisandrin ameliorates cognitive impairment and attenuates Aβ deposition in APP/PS1 transgenic mice: involvement of adjusting neurotransmitters and their metabolite changes in the brain.Drug discovery, development and delivery in Alzheimer's disease.Mithramycin A Alleviates Cognitive Deficits and Reduces Neuropathology in a Transgenic Mouse Model of Alzheimer's Disease.Computational Screening and Exploration of Disease-Associated Genes in Alzheimer's Disease.Can cloud-based tools accelerate Alzheimer's disease drug discovery?Pharmacotherapy for Dementia: A Practical Approach to the Use of Cholinesterase Inhibitors and Memantine.Solvation-Guided Design of Fluorescent Probes for Discrimination of Amyloids.Identification of novel acetylcholinesterase inhibitors designed by pharmacophore-based virtual screening, molecular docking and bioassay
P2860
Q26738355-7580F795-981B-415F-BA6F-87945B3E8368Q36166587-C6C28F0A-C38F-4D04-9FAB-DD4C4B841703Q36515128-4F86493C-C678-49B8-BC13-454D12585B95Q36597696-E2BF45D7-DE85-48D7-BFF4-1C298E5FFA16Q36847399-30282195-05D2-44A7-A858-6DE146455F76Q37494873-D7A7578C-00D9-4292-BBEA-ABB2FF03859FQ37614594-9BF14EDF-4EA0-4861-A410-7D430D410C25Q38639674-0D06CE93-1BCA-4991-977E-F22506A31286Q38808542-10088B6F-40F2-446D-873D-8009EAC87123Q38905278-31A48527-4E4E-49E9-9EBB-69B8A784CD9BQ38946790-BAC0BE3E-9B47-4D29-81B3-A2BAE3EF74A7Q42077676-F6C95098-6C89-4809-91AC-60809616B1B6Q42118491-A8A35844-3007-46D3-8A14-AB53B2A0EA4AQ47555674-1D290D63-A638-4778-9C15-5DB7D37F0D27Q47721409-106866B2-3379-4623-8FF8-D45AD7DF2638Q49484168-BAB8AE52-D402-4432-A352-C01DF5E7996FQ50520724-0DF67612-FB53-4F54-A9BC-EC301B84ED8AQ50609821-B9BC0669-8586-4A2A-BF39-4B7CE61A8C8BQ53372164-CA7E5791-456B-4293-B8E2-7020A3E6DD3DQ53377510-02D7958F-FBE4-471D-B9AF-0DD4F3C8A4CFQ55053546-1388AC1D-1D96-4868-A43A-34C1BA950042Q57296260-E0A2EF33-3283-437C-840C-235641A0FDC0
P2860
description
2015 nî lūn-bûn
@nan
2015 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2015 թվականի մարտին հրատարակված գիտական հոդված
@hy
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
name
Advances in Alzheimer's disease drug development
@ast
Advances in Alzheimer's disease drug development
@en
Advances in Alzheimer's disease drug development
@nl
type
label
Advances in Alzheimer's disease drug development
@ast
Advances in Alzheimer's disease drug development
@en
Advances in Alzheimer's disease drug development
@nl
prefLabel
Advances in Alzheimer's disease drug development
@ast
Advances in Alzheimer's disease drug development
@en
Advances in Alzheimer's disease drug development
@nl
P2860
P3181
P1433
P1476
Advances in Alzheimer's disease drug development
@en
P2093
Michael S Rafii
P2860
P2888
P3181
P356
10.1186/S12916-015-0297-4
P407
P5008
P577
2015-03-25T00:00:00Z
P5875
P6179
1022291737